menu
    • menu
    [{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OR-449","moa":"NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphagen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OR-449","moa":"SF-1\/ NR5A1","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orphagen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"OR-449","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orphagen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orphagen Pharmaceuticals","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"OR-812","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Orphagen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Orphagen Pharmaceuticals \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"Orphagen Pharmaceuticals \/ NIDDK"}]

    Find Clinical Drug Pipeline Developments & Deals by Orphagen Pharmaceuticals

    Menu

    Orphagen Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR-812

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : NIDDK

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Orphagen Receives NIH Funding to Advance Inflammatory Bowel Disease Drug

                            Details : The funding will support the development of the small molecule OR-812, a selective nuclear receptor antagonist, as a novel oral therapeutic for treatment of ulcerative colitis and Crohn’s disease

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : OR-812

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : NIDDK

                            Deal Size : $1.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR-449

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphagen Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for OR-449 for the Treatment of ...

                            Details : OR-449 is a selective, first-in-class, potent and orally bioavailable small molecule antagonist to SF-1 or NR5A1, which is essential for the growth and development of adrenal gland. It is being developed for ACC and other cancers known to express a high ...

                            Product Name : OR-449

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : OR-449

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR-449

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022

                            Details : OR-449 is a potent, selective, and orally bioavailable small molecule antagonist to steroidogenic factor-1 (SF-1 or NR5A1), a nuclear receptor and a transcription factor essential for the growth and development of the adrenal gland.

                            Product Name : OR-449

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 11, 2022

                            Lead Product(s) : OR-449

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Orphagen Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OR-449

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Orphagen Pharmaceuticals Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class Steroidog...

                            Details : OR-449, a potent SF-1 antagonist exhibits striking anti-proliferative activity in the rat Leydig tumor cell (LCT) line R2C, inhibiting DNA synthesis by >90% at 1 mM with an estimated IC50 of 68 nM.

                            Product Name : OR-449

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : OR-449

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth